478 results about "In situ hybridisation" patented technology

Conjugate compositions are disclosed that include a specific-binding moiety covalently coupled to a nanoparticle through a heterobifunctional polyalkyleneglycol linker. In one embodiment, a conjugates is provided that includes a specific-binding moiety and a fluorescent nanoparticle coupled by a heterobifunctional PEG linker. Fluorescent conjugates according to the disclosure can provide exceptionally intense and stable signals for immunohistochemical and in situ hybridization assays on tissue sections and cytology samples, and enable multiplexing of such assays.

Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.

This invention relates to imaging, such as by expansion microscopy, labelling, and analyzing biological samples, such as cells and tissues, as well as reagents and kits for doing so.

The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.

ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.

The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.

Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.

Scanning and analysis of cytology and histology samples uses a flatbed scanner to capture images of the structures of interest such as tumor cells in a manner that results in sufficient image resolution to allow for the analysis of such common pathology staining techniques as ICC (immunocytochemistry), IHC (immunohistochemistry) or in situ hybridization. Very large volumes of such material are scanned in order to identify cells or clusters of cells which are positive or warrant more detailed examination, and if analysis at higher resolution is necessary, information regarding these positive events is transferred to a secondary microscope, such as a conventional scanning microscope, to allow further analysis and review of the selected regions of the slide containing the sample.

Methods and apparatuses for gently removing embedding media from biological samples at temperatures below the embedding medium melting point with liquid composition using batch methods or automated instruments prior to immunohistochemical (IHC), in situ hybridization (ISH) or other special staining or histochemical or cytochemical manipulations.

Novel methods of probing multiple targets in a biological sample are provide whereby the targets are DNA, RNA and protein. The method comprises subjecting the sample to an in situ hybridization reaction using a labeled nucleic acid probe that binds an RNA target, observing a signal, and optionally removing the signal. The method further comprises an antigen retrieval protocol, observing a signal, removing the signal, and optionally applying a protease treatment to access the sample's DNA targets by subjecting the sample to an in situ hybridization reaction using a labeled nucleic acid probe, observing a signal from the labeled DNA targets, and optionally removing the signal.

Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.

The present invention provides methods for preparing cells with highly condensed chromosomes, such as sperm, and methods for detecting and quantifying specific cellular target molecules in intact cells. Specifically, methods are provided for detecting chromosomes and chromosomal abnormalities, including aneuploidy, in intact cells using fluorescence in situ hybridization of cells in suspension, such as sperm cells.

The invention relates to a newly cloned full-length sequence of a long chain non-coding RNA (Ribonucleic Acid) gene and an application method thereof. The gene can be detected in a separation sample by methods including a hybrid method or an amplification method; and the gene can be used as a tumor marker, in particular a marker of liver cancer. According to the gene sequence, a real-time quantification PCR (Polymerase Chain Reaction) primer and an in situ hybridization probe are designed and synthesized; and by detecting the expression level of the long chain non-coding RNA in a liver cancer clinical case sample, expression of the long chain non-coding RNA in liver cancer is up-regulated remarkably, and prognosis of patients with liver caner with high expression of long chain non-coding RNA is poorer. According to the gene sequence, a RNA eukaryotic expression vector in a short hairpin structure for closing the expression of the long chain non-coding RNA by RNA interference is designed and synthesized; and the expression of the long chain non-coding RN in a liver cancer cell line A is inhibited successfully by using the vector.

The invention relates to a preparation method for probes related to breast cancer molecular markers and to preparation of a breast cancer fluorescence in situ hybridization detection kit by using the probes. The breast cancer fluorescence in situ hybridization detection kit can be prepared from HER2, TOP2A and AGTR1 gene probes prepared by using the method provided in the invention, human chromosome 17 counting probe, hybridization buffer, unlabelled competitive DNA and DAPI counter strain; application of the kit enables the detection rate of breast cancers to be substantially improved and type sorting of breast cancers to be more accurate and provides guidance to formulation of an individual therapeutic schedule and selection of proper therapeutic drugs, thereby lowering down mortality, reducing recurrence risk and achieving the goal of optimizing the effect of diagnosis and treatment.

The invention discloses an in situ hybridization probe, a reagent and an application of long non-coding RNA LOC401317. The long non-coding RNA LOC401317 can be used for preparing a prognosis preparation for a patient with nasopharyngeal carcinoma, and particularly a kit for predicting prognosis of the patient with the nasopharyngeal carcinoma employing an in situ hybridization detection method is prepared. A research proves that expression of the LOC401317 in a nasopharyngeal carcinoma tissue is lowered, and the patient with the nasopharyngeal carcinoma in low-expression LOC401317 is worse than the patient with the nasopharyngeal carcinoma in high-expression LOC401317 in prognosis, therefore, expression of the LOC401317 is applied to prognosis prediction of the patient with nasopharyngeal carcinoma; a powerful molecular biology basis can be provided for prognosis of the patient with the nasopharyngeal carcinoma; and the long non-coding RNA LOC401317 has profound clinical significance and important popularization and application prospects.

The invention relates to a method for detecting bacteria in drinking water and surface water, especially a method for simultaneous specific detection of bacteria from the Legionella species and the Legionella pneumophila species by in situ hybridization. The invention also relates to a method for specific detection of faecal streptococci by in situ-hybridization and a method for simultaneous specific detection of coliform bacteria and bacteria of the Escherichia coli species, in addition to corresponding oligonucleotide probes and kits enabling said inventive method to be carried out.

Three kinds of tissues including cancer tissue, precancerosis and corresponding normal tissue are sliced up, dyed, marked, and positioned. Receptor holes are prepared by leading designed lattice array mould paper to paste on surface of wax block of receptor. Wax block with tissue core bar is prepared by using perforating needle and puncture needle for tissue. Common cancer such as lung cancer, nasopharyngeal carcinoma, oesophagus cancer etc. and having integrated clinical data and pathology features are selected. Through in situ hybridization, testing mRNA of relevant gene and expression of protein on tissue chip, consistent result between the invented product and traditional test is validated. In the product, cellular morphology is clear and even, and there is no fallen off tissue point. The invention is applicable to filter cancers, early diagnosis and forecasting prognosis.

The invention belongs to the field of biotechnology, and discloses a FISH (fluorescence in situ hybridization) probe, a kit and a detection method for detecting BCR/ABL fusion gene free from repetitive sequence. A BCR gene and ABL gene are used as templates to perform polymerase chain reaction on non-repetitive sequence in the BCR gene and ABL gene, the amplification product is DNA (deoxyribonucleic acid) fragments with 350-800 different base-pairs, the repetitive sequences in the BCR gene and ABL gene are eliminated so as to form the product free from repetitive sequence; after the product is in fluorescence labeling, the BCR gene and ABL gene free from repetitive FISH are obtained for the BCR gene and ABL gene FISH detection. The BCR/ABL fusion gene FISH probe obtained by the invention can be used for eliminating the repetitive sequence, the non-specific background signal of the FISH probe can be obviously reduced, and the specificity of the FISH probe is improved.

The invention discloses a preparation method for a gill tissue paraffin section. The preparation method comprises the following steps: fixing, decalcifying, dehydrating, transparentizing, carrying out paraffin permeation, embedding, slicing, sticking sections, expanding the sections, de-waxing and rehydrating, staining, re-staining, sealing and the like. Compared with an existing paraffin section manufacturing method, an operation process of dehydrating, transparentizing and immersing by wax is improved; the preparation fixing and tissue wax immersing effects of gill tissue paraffin are improved; a slicing problem when the gill tissue paraffin section is prepared is improved; the structure definition of the gill tissue section is greatly improved; a plurality of problems in a gill tissue manufacturing process in the prior art are solved. The preparation method is good for antigen positioning of immunocytochemical staining, so that when experiments including in-situ hybridization, immunohistochemistry, immunofluorescence and the like are carried out on the gill tissue paraffin section, tissue distribution and cell positioning of some genes and proteins can be displayed, and further feasible conditions are provided for carrying out gill research on levels of cells, genes and proteins.

The invention relates to methods of categorizing a cervical tissue or cytology sample by performing an in situ hybridization assay using an antisense E6 or E7 probe on a cervical tissue sample, wherein the antisense E6 or E7 probe can simultaneously detect HPV DNA and HPV RNA; detecting the presence of HPV nucleic acid; and categorizing the cervical tissue sample based on HPV nucleic acid expression.

Relating to methods able to conduct fast histochemistry and other analyses in plant tissues, the invention specifically relates to an embedding medium and a direct frozen section method. The embedding medium is composed of polyvinyl alcohol, polyethylene glycol, carboxymethylcellulose sodium, glycerol, formaldehyde, collagen, plant gel, and deionized water. According to the frozen section method, a plant material is not fixed, and a sample subjected to histochemical staining and other treatments or a fresh tissue is wrapped on a sample table directly to perform frozen section. The method solves the problem that in the microscopic observation of phytohistochemistry, immunolocalization, in-situ hybridization and other studies, a target chemical substance is easy to dissolve in a fixation agent, and is impossible to be fixed first and then sectioned, or the target chemical substance dissolves in an alcohol substance and is impossible to be dehydrated by ethanol.

Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread. Amplifications, duplications and/or deletions in the subject genome(s) can be detected. Also provided is a method of determining the absolute copy numbers of substantially all RNA or DNA sequences in subject cell(s) or cell population(s).

The present invention relates to a gene probe composition and a kit for acute lymphocytic leukemia detection. The gene probe composition comprises a TEL gene probe, an AML1 gene probe, a PAX5 gene probe, a P16 gene probe and an IKZF1 gene probe. The present invention further provides an acute lymphocytic leukemia fluorescence in situ hybridization detection kit, wherein the kit comprises the gene probe composition. With the kit, concurrent five gene detection can be performed on the same sample even the single leukemia cell, and detection capability and efficiency are significantly improved.

The present invention discloses an apparatus for thin-layer cell smear preparation and in-situ hybridization, comprising at least one positioning device and a sealing device. The positioning device comprises at least one first opening. When the positioning device is set on a carrier device, the wall of the first opening and the carrier device form a cavity. The cavity is used to accommodate a cell suspension. The sealing device is provided on the positioning device for sealing the cavity to form an enclosed space.

The invention provides a method for monitoring the quality of in situ hybridization analysis of a nuclear DNA target in a tissue or cell sample using a mitochondrial DNA probe as an internal control. The invention also provides a reagent for in situ hybridization detection of a nuclear DNA target and a mitochondrial DNA target in a tissue or cell sample.